Ranbaxy Laboratories increased 10.8 per cent to close the day at Rs 161.05 on news that the company received Medicines and Healthcare Products Regulatory Agency (UK) and Therapeutic Goods Administration (Australia) approvals for good manufacturing practice for its plant at Paonta Sahib in India.
The stock made an intraday high of Rs 162.9 and a low of Rs 146.15 with trading volumes of 25.14 lakh shares (about two-times higher than its two-week average). The scrip made a 52-week high of Rs 613.7 (June 19, 2008) and a low of Rs 133.15 (March 12, 2009).
